Allogene Therapeutics
Sacha Prashad is a highly experienced professional in the field of oncology and stem cell biology. Currently serving as Director of Translational Oncology at Allogene Therapeutics, Sacha has held various roles within the organization including Associate Director and Senior Manager in the same department. Prior experience includes a position as Senior Scientist at Notable Labs and involvement as a Junior Investigator Committee member with the International Society of Stem Cell Research. Sacha holds a Doctor of Philosophy (PhD) degree in stem cell biology from UCLA.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.